Purpose of Review <p>Therapeutic options for chronic kidney disease (CKD) include angiotensin-converting enzyme (ACE) inhibitors, angiotensin-2 receptor blockers (ARBs), sodium-glucose cotransporter-2 inhibitors (SGLT2i), selective mineralocorticoid receptor antagonists (MRAs), and glucagon-like peptide-1 (GLP-1) receptor agonists. These treatments aim to slow the progression of CKD, particularly in individuals with hypertension and diabetes mellitus. This review appraises the potential benefits of colchicine for patients with CKD.</p> Recent Findings <p>Hyperuricemia is often present in patients with CKD. Mendelian randomization analyses found no evidence for a causal role of serum urate level in estimated glomerular filtration rate decline or incident CKD, suggesting that serum urate reduction alone would not prevent incident CKD. It is, therefore, not surprising that randomized controlled trials of urate-lowering therapies to slow the progression of CKD have been disappointing in mitigating CKD progression.</p> <p>Acute and chronic inflammation are common in individuals with CKD, as is fibrosis, a common mediator in CKD progression. Colchicine has been used for over 2000 years for acute gout flares. Preclinical animal studies suggest colchicine has anti-albuminuric, anti-inflammatory, and anti-fibrotic effects. Moreover, colchicine is associated with a lower risk of adverse kidney outcomes and may slow the progression of CKD.</p> Summary <p>Colchicine may offer an additional pharmacotherapeutic option to slow CKD progression. Both animal and observational studies provide evidence to support this assertion. Randomized controlled trials are warranted to assess the renoprotective effects of colchicine in patients with CKD.</p>